HDII Stock Overview
Hypertension Diagnostics, Inc. designs, develops, manufactures, and markets proprietary noninvasive medical devices that detect subtle changes in the elasticity of arteries in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Hypertension Diagnostics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0002 |
| 52 Week High | US$0.004 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 19,900.00% |
| 3 Month Change | -84.62% |
| 1 Year Change | -93.55% |
| 3 Year Change | -98.95% |
| 5 Year Change | -86.67% |
| Change since IPO | -99.99% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| HDII | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | 1.8% | 1.2% |
| 1Y | -93.5% | -0.5% | 24.9% |
Return vs Industry: HDII underperformed the US Medical Equipment industry which returned -0.7% over the past year.
Return vs Market: HDII underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| HDII volatility | |
|---|---|
| HDII Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 7.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: HDII's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine HDII's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | n/a | Liangjian Peng | www.hypertensiondiagnostics.com |
Hypertension Diagnostics, Inc. designs, develops, manufactures, and markets proprietary noninvasive medical devices that detect subtle changes in the elasticity of arteries in the United States and internationally. It offers CVProfilor, which allows a physician to non-invasively assess the elasticity of small and large arteries, of which small artery elasticity is the earliest and sensitive marker of cardiovascular disease. The company offers CVProfilor DO-2020, which provides a patient’s arterial elasticity indices used in the assessment for underlying vascular disease; CVProfilor MD-3000 that offers a sensitive and specific guide to the presence of blood vessel disease; and HD/PulseWave CR-2000 research cardiovascular profiling system, which provides researchers and scientists with a non-invasive means to assess arterial elasticity in support of human research in various areas.
Hypertension Diagnostics, Inc. Fundamentals Summary
| HDII fundamental statistics | |
|---|---|
| Market cap | US$56.96k |
| Earnings (TTM) | -US$125.39k |
| Revenue (TTM) | US$3.79m |
0.0x
P/S Ratio0.0x
P/E RatioIs HDII overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HDII income statement (TTM) | |
|---|---|
| Revenue | US$3.79m |
| Cost of Revenue | US$2.84m |
| Gross Profit | US$954.47k |
| Other Expenses | US$1.08m |
| Earnings | -US$125.39k |
Last Reported Earnings
Dec 31, 2018
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did HDII perform over the long term?
See historical performance and comparison